International Journal of Clinical and Laboratory Research

, Volume 29, Issue 1, pp 22–25

Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia

  • N. Nakamura
  • T. Hamazaki
  • M. Ohta
  • K. Okuda
  • M. Urakaze
  • S. Sawazaki
  • K. Yamazaki
  • A. Satoh
  • R. Temaru
  • Y. Ishikura
  • M. Takata
  • M. Kishida
  • M. Kobayashi
Original

DOI: 10.1007/s005990050057

Cite this article as:
Nakamura, N., Hamazaki, T., Ohta, M. et al. Int J Clin Lab Res (1999) 29: 22. doi:10.1007/s005990050057

Abstract

HMG-CoA reductase inhibitors reduce serum total cholesterol concentrations and the risk of coronary heart disease in patients with hypercholesterolemia. Recently, it has been reported that patients with combined hyperlipidemia are also at risk of coronary heart disease. However, HMG-CoA reductase inhibitor therapy alone does not sufficiently reduce serum triglyceride concentrations. Epidemiological and clinical evidence has shown that fish oil can lower plasma lipid levels, especially triglycerides. Consequently, we investigated the effects of the combination of HMG-CoA reductase inhibitors and eicosapentaenoic acid, a major component of fish oil, on hyperlipidemia. We administered 900–1,800 mg/day of the ethyl ester of eicosapentaenoic acid to patients with hyperlipidemia who had been treated with HMG-CoA reductase inhibitors for 30±6 months (means±SE). Serum total cholesterol and triglyceride concentrations were significantly decreased 3 months after the administration of eicosapentaenoic acid (from 5.63±0.23 mmol/l to 5.02±0.20 mmol/l,P<0.05; from 2.07±0.41 mmol/l to 1.08±0.17 mmol/l,P<0.01, respectively). Serum high-density lipoprotein-cholesterol concentrations were significantly increased after the treatment (from 1.23±0.12 mmol/l to 1.34±0.13 mmol/l,P<0.05). Plasma eicosapentaenoic acid concentrations and the ratio to arachidonic acid in plasma were also significantly increased 3 months after the treatment (from 101.9±8.1 mg/l to 181.8±23.9 mg/l,P<0.001; from 0.640±0.075 to 1.211±0.170,P<0.001, respectively). These results suggested that the combination therapy of HMG-CoA reductase inhibitors and eicosapentaenoic acid was effective for patients with hyperlipidemia.

Key words

Arachidonic acidEicosapentaenoic acidHMG-CoA reductase inhibitorRemnant-like particles cholesterol

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • N. Nakamura
    • 1
  • T. Hamazaki
    • 2
  • M. Ohta
    • 3
  • K. Okuda
    • 3
  • M. Urakaze
    • 1
  • S. Sawazaki
    • 1
  • K. Yamazaki
    • 1
  • A. Satoh
    • 1
  • R. Temaru
    • 1
  • Y. Ishikura
    • 1
  • M. Takata
    • 1
  • M. Kishida
    • 1
  • M. Kobayashi
    • 1
  1. 1.The First Department of Internal MedicineToyama Medical and Pharmaceutical UniversityToyama-city, ToyamaJapan
  2. 2.The Department of Clinical Application, Research Institute of Wakan-YakuToyama Medical and Pharmaceutical UniversityToyama-city, ToyamaJapan
  3. 3.Department of Internal MedicineTakaoka City HospitalTakaoka-city, ToyamaJapan